{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=HER2-targeted+Therapy&page=3",
    "query": {
      "intervention": "HER2-targeted Therapy",
      "page": 3
    },
    "page_size": 10
  },
  "pagination": {
    "page": 3,
    "page_size": 10,
    "total_count": 110,
    "total_pages": 11,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=HER2-targeted+Therapy&page=4&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=HER2-targeted+Therapy&page=2&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-13T23:09:37.994Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT06666439",
      "title": "Longitudinal Tumor Burden Quantification Using Circulating Tumor DNA in Metastatic Lobular Breast Cancer",
      "overall_status": "RECRUITING",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Metastatic Invasive Lobular Carcinoma (mILC)"
      ],
      "interventions": [
        {
          "name": "circulating tumor DNA (ctDNA)",
          "type": "DIAGNOSTIC_TEST"
        }
      ],
      "intervention_types": [
        "DIAGNOSTIC_TEST"
      ],
      "sponsor": "Julia Foldi",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "18 Years and older · Female only"
      },
      "enrollment_count": 20,
      "start_date": "2024-12-12",
      "completion_date": "2029-10-31",
      "has_results": false,
      "last_update_posted_date": "2026-01-20",
      "last_synced_at": "2026-10-13T23:09:37.994Z",
      "location_count": 1,
      "location_summary": "Pittsburgh, Pennsylvania",
      "locations": [
        {
          "city": "Pittsburgh",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06666439"
    },
    {
      "nct_id": "NCT04869943",
      "title": "Efficacy Evaluation of Enobosarm Monotherapy in Treatment of AR+/ER+/HER2- Metastatic Breast Cancer",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Metastatic Breast Cancer"
      ],
      "interventions": [
        {
          "name": "Enobosarm",
          "type": "DRUG"
        },
        {
          "name": "Exemestane",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Veru Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "100 Years",
        "sex": "ALL",
        "summary": "18 Years to 100 Years"
      },
      "enrollment_count": 52,
      "start_date": "2021-10-12",
      "completion_date": "2024-01-09",
      "has_results": false,
      "last_update_posted_date": "2024-01-26",
      "last_synced_at": "2026-10-13T23:09:37.994Z",
      "location_count": 34,
      "location_summary": "Chandler, Arizona • Gilbert, Arizona • Glendale, California + 29 more",
      "locations": [
        {
          "city": "Chandler",
          "state": "Arizona"
        },
        {
          "city": "Gilbert",
          "state": "Arizona"
        },
        {
          "city": "Glendale",
          "state": "California"
        },
        {
          "city": "Greenbrae",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04869943"
    },
    {
      "nct_id": "NCT02286843",
      "title": "Can HER2 Targeted PET/CT Imaging Identify Unsuspected HER2 Positive Breast Cancer Metastases, Which Are Amenable to HER2 Targeted Therapy?",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Breast Cancer Metastases",
        "HER2 Positive Breast"
      ],
      "interventions": [
        {
          "name": "89Zr-trastuzumab",
          "type": "RADIATION"
        },
        {
          "name": "PET/CT scan",
          "type": "DEVICE"
        },
        {
          "name": "89Zr-pertuzumab",
          "type": "RADIATION"
        }
      ],
      "intervention_types": [
        "RADIATION",
        "DEVICE"
      ],
      "sponsor": "Memorial Sloan Kettering Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "18 Years and older · Female only"
      },
      "enrollment_count": 49,
      "start_date": "2014-11-06",
      "completion_date": "2020-06-30",
      "has_results": true,
      "last_update_posted_date": "2021-06-18",
      "last_synced_at": "2026-10-13T23:09:37.994Z",
      "location_count": 1,
      "location_summary": "New York, New York",
      "locations": [
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02286843"
    },
    {
      "nct_id": "NCT07053085",
      "title": "A Study of Surgery and Radiotherapy in People With Breast Cancer",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Metastatic Breast Cancer",
        "HER2-positive Breast Cancer"
      ],
      "interventions": [
        {
          "name": "Lumpectomy or mastectomy",
          "type": "PROCEDURE"
        },
        {
          "name": "Radiotherapy",
          "type": "RADIATION"
        },
        {
          "name": "Trastuzumab, Pertuzumab, Paclitaxel, or a combination of these drugs",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "PROCEDURE",
        "RADIATION",
        "DRUG"
      ],
      "sponsor": "Memorial Sloan Kettering Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 178,
      "start_date": "2025-09-17",
      "completion_date": "2029-09-17",
      "has_results": false,
      "last_update_posted_date": "2026-05-14",
      "last_synced_at": "2026-10-13T23:09:37.994Z",
      "location_count": 7,
      "location_summary": "Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more",
      "locations": [
        {
          "city": "Basking Ridge",
          "state": "New Jersey"
        },
        {
          "city": "Middletown",
          "state": "New Jersey"
        },
        {
          "city": "Montvale",
          "state": "New Jersey"
        },
        {
          "city": "Commack",
          "state": "New York"
        },
        {
          "city": "Harrison",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07053085"
    },
    {
      "nct_id": "NCT03054363",
      "title": "Tucatinib, Palbociclib and Letrozole in Metastatic Hormone Receptor Positive and HER2-positive Breast Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Breast Cancer"
      ],
      "interventions": [
        {
          "name": "Tucatinib in Combination with Palbociclib and Letrozole",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of Colorado, Denver",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "100 Years",
        "sex": "FEMALE",
        "summary": "18 Years to 100 Years · Female only"
      },
      "enrollment_count": 42,
      "start_date": "2017-11-27",
      "completion_date": "2023-02-07",
      "has_results": true,
      "last_update_posted_date": "2023-11-13",
      "last_synced_at": "2026-10-13T23:09:37.994Z",
      "location_count": 6,
      "location_summary": "Tucson, Arizona • Aurora, Colorado • Chicago, Illinois + 3 more",
      "locations": [
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Albuquerque",
          "state": "New Mexico"
        },
        {
          "city": "Stony Brook",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03054363"
    },
    {
      "nct_id": "NCT05785741",
      "title": "A Study of DB-1310 in Advanced/Metastatic Solid Tumors",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Advanced Solid Tumor"
      ],
      "interventions": [
        {
          "name": "DB-1310",
          "type": "DRUG"
        },
        {
          "name": "Trastuzumab",
          "type": "DRUG"
        },
        {
          "name": "Osimertinib",
          "type": "DRUG"
        },
        {
          "name": "capecitabine",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "DualityBio Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 1000,
      "start_date": "2023-08-17",
      "completion_date": "2028-04-30",
      "has_results": false,
      "last_update_posted_date": "2026-04-06",
      "last_synced_at": "2026-10-13T23:09:37.994Z",
      "location_count": 15,
      "location_summary": "Sacramento, California • Santa Monica, California • Coral Gables, Florida + 12 more",
      "locations": [
        {
          "city": "Sacramento",
          "state": "California"
        },
        {
          "city": "Santa Monica",
          "state": "California"
        },
        {
          "city": "Coral Gables",
          "state": "Florida"
        },
        {
          "city": "Margate",
          "state": "Florida"
        },
        {
          "city": "Orlando",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05785741"
    },
    {
      "nct_id": "NCT04143711",
      "title": "Study of DF1001 in Patients With Advanced Solid Tumors",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Solid Tumor, Adult"
      ],
      "interventions": [
        {
          "name": "DF1001",
          "type": "DRUG"
        },
        {
          "name": "Nivolumab",
          "type": "DRUG"
        },
        {
          "name": "Nab paclitaxel",
          "type": "DRUG"
        },
        {
          "name": "Sacituzumab Govitecan-hziy",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Dragonfly Therapeutics",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 270,
      "start_date": "2019-11-11",
      "completion_date": "2025-12-05",
      "has_results": false,
      "last_update_posted_date": "2026-03-18",
      "last_synced_at": "2026-10-13T23:09:37.994Z",
      "location_count": 16,
      "location_summary": "Irvine, California • Los Angeles, California • San Diego, California + 13 more",
      "locations": [
        {
          "city": "Irvine",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Westwood",
          "state": "Kansas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04143711"
    },
    {
      "nct_id": "NCT04147819",
      "title": "A First in Human Study of BAY2701439 to Look at Safety, How the Body Absorbs, Distributes and Excretes the Drug, and How Well the Drug Works in Participants With Advanced Cancer Expressing the HER2 Protein",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Cancers With HER2 Expression"
      ],
      "interventions": [
        {
          "name": "BAY2701439",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Bayer",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 14,
      "start_date": "2020-07-02",
      "completion_date": "2023-09-26",
      "has_results": false,
      "last_update_posted_date": "2024-09-27",
      "last_synced_at": "2026-10-13T23:09:37.994Z",
      "location_count": 4,
      "location_summary": "Baltimore, Maryland • St Louis, Missouri • New York, New York + 1 more",
      "locations": [
        {
          "city": "Baltimore",
          "state": "Maryland"
        },
        {
          "city": "St Louis",
          "state": "Missouri"
        },
        {
          "city": "New York",
          "state": "New York"
        },
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04147819"
    },
    {
      "nct_id": "NCT00968968",
      "title": "Continued HER2 Suppression With Lapatinib Plus Trastuzumab Versus Trastuzumab Alone",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Cancer"
      ],
      "interventions": [
        {
          "name": "Lapatinib",
          "type": "DRUG"
        },
        {
          "name": "Trastuzumab",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "DRUG",
        "BIOLOGICAL"
      ],
      "sponsor": "Novartis Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "18 Years and older · Female only"
      },
      "enrollment_count": 37,
      "start_date": "2010-01-20",
      "completion_date": "2018-03-30",
      "has_results": true,
      "last_update_posted_date": "2019-06-10",
      "last_synced_at": "2026-10-13T23:09:37.994Z",
      "location_count": 112,
      "location_summary": "Chandler, Arizona • Flagstaff, Arizona • Gilbert, Arizona + 93 more",
      "locations": [
        {
          "city": "Chandler",
          "state": "Arizona"
        },
        {
          "city": "Flagstaff",
          "state": "Arizona"
        },
        {
          "city": "Gilbert",
          "state": "Arizona"
        },
        {
          "city": "Mesa",
          "state": "Arizona"
        },
        {
          "city": "Mesa",
          "state": "Arizona"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00968968"
    },
    {
      "nct_id": "NCT00343759",
      "title": "Presurgical Therapy With Lapatinib to Explore Molecular Determinants of Response to EGFR/erbB2 Targeted Therapy",
      "overall_status": "WITHDRAWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Breast Cancer"
      ],
      "interventions": [
        {
          "name": "Lapatinib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of Pennsylvania",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "18 Years and older · Female only"
      },
      "enrollment_count": 0,
      "start_date": "2006-06",
      "completion_date": "2009-12",
      "has_results": false,
      "last_update_posted_date": "2015-12-11",
      "last_synced_at": "2026-10-13T23:09:37.994Z",
      "location_count": 1,
      "location_summary": "Philadelphia, Pennsylvania",
      "locations": [
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00343759"
    }
  ]
}